Megan Ritchie Odio

Megan Ritchie Odio has nearly a decade of experience in clinical operations across oncology, immunology, and inflammatory diseases, with experience spanning global Phase II and Phase III programs. Her expertise includes clinical operations, CRO and vendor oversight, site selection and startup, regulatory submissions, data management, and cross-functional execution of complex clinical trials.

Most recently, Megan served as Senior Clinical Trial Manager at Apogee Therapeutics, directing clinical operations for a global Phase III program and previously leading European operations for a Phase II program. Prior to Apogee, at Deciphera Pharmaceuticals, she worked on global Phase III oncology programs in gastrointestinal stromal tumors and sarcoma and led clinical operations through the database lock of a pivotal study that supported FDA approval of ROMVIMZA (vimseltinib). Earlier in her career, she held roles at DrugDev, an IQVIA company, and Brigham and Women’s Hospital.

Megan earned an MPH in Health Services Management and Policy from Tufts University School of Medicine and a BS in Biology from Boston College, where she also completed a Certificate in Clinical Research.